Canine Leptospirosis: Clinical Signs, Diagnosis, and Zoonotic Risk

Introduction

Canine leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. The disease represents a significant diagnostic challenge in veterinary practice due to its variable clinical presentation, overlapping signs with other febrile and hepatorenal conditions, and the requirement for specialized laboratory confirmation. Beyond its impact on canine health, Leptospira infection in dogs carries substantial zoonotic risk, positioning the disease as a key component of One Health surveillance programs. This article provides an exhaustive review of the clinical signs, diagnostic modalities, and zoonotic implications of canine leptospirosis, with emphasis on serovar epidemiology and the biophysical principles underlying current detection methods.

Etiology and Serovar Epidemiology

Pathogenic Leptospira are classified into over 250 serovars grouped within 24 serogroups based on lipopolysaccharide (LPS) antigenic structure. The species Leptospira interrogans sensu stricto contains the majority of serovars pathogenic to dogs, including Canicola, Icterohaemorrhagiae, Grippotyphosa, Pomona, Bratislava, and Australis [1, 2]. Historically, serovars Canicola and Icterohaemorrhagiae were considered the primary canine-adapted serovars, but epidemiological shifts over recent decades have broadened the spectrum of serovars implicated in clinical disease [3, 4].

Serovar prevalence varies geographically and temporally, influenced by reservoir host populations, climate, and urbanization patterns. In North America, serovars Grippotyphosa, Pomona, and Bratislava have emerged as common causes of canine leptospirosis, while Icterohaemorrhagiae remains prevalent in urban environments with high rat densities [5, 6]. European studies report a predominance of serogroups Australis (serovar Bratislava), Grippotyphosa, and Icterohaemorrhagiae [7, 8]. Serovar Canicola, once the most frequently isolated serovar from dogs, has declined in many regions, likely due to widespread vaccination targeting this serovar [9].

The maintenance of Leptospira in the environment depends on chronic renal carriage in reservoir hosts. Rodents, particularly Rattus norvegicus, serve as the primary reservoir for serovar Icterohaemorrhagiae, while wildlife such as raccoons, skunks, and opossums maintain serovars Grippotyphosa and Pomona [10, 11]. Dogs can act as incidental hosts or, in the case of serovar Canicola, as maintenance hosts capable of sustaining transmission cycles [12].

Pathogenesis

Infection occurs through direct or indirect contact of mucous membranes or abraded skin with urine or water contaminated by leptospires. The spirochetes penetrate the host via active motility and adhesion to extracellular matrix components, facilitated by surface proteins such as LigA, LigB, and LipL32 [13, 14]. Following a leptospiremic phase lasting 4 to 12 days, organisms disseminate to target organs, particularly the kidneys, liver, lungs, and eyes.

Renal pathology is characterized by interstitial nephritis and tubular necrosis, driven by the host inflammatory response and direct bacterial cytotoxicity [15]. Leptospires colonize the proximal renal tubules, where they evade immune clearance and are shed in urine for weeks to months after clinical recovery [16]. Hepatic involvement manifests as centrilobular necrosis and canalicular cholestasis, leading to icterus in severe cases [17]. Pulmonary hemorrhage, a life-threatening complication, results from endothelial damage and immune complex deposition in alveolar capillaries [18].

Clinical Signs

The clinical presentation of canine leptospirosis ranges from subclinical infection to acute, rapidly fatal disease. Incubation periods typically span 5 to 14 days. Clinical signs are often categorized by the predominant organ system affected, though overlap is common.

Renal form: Polyuria, polydipsia, vomiting, dehydration, and oliguric or anuric acute kidney injury (AKI). Azotemia, hyperphosphatemia, and isosthenuria are characteristic laboratory findings [19].

Hepatic form: Icterus, anorexia, lethargy, and vomiting. Serum biochemistry reveals elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin [20].

Vascular form: Pulmonary hemorrhage with dyspnea, tachypnea, and hemoptysis. Thoracic radiographs may show diffuse interstitial to alveolar patterns [21].

Other manifestations: Fever, myalgia, stiffness, conjunctival injection, uveitis, and coagulopathies (thrombocytopenia, prolonged clotting times) [22]. Subclinical infections are common in endemic areas, with seropositive dogs showing no overt signs but serving as potential urinary shedders [23].

A summary of clinical signs by organ system is presented in Table 1.

Table 1. Clinical Signs of Canine Leptospirosis by Organ System

Diagnostic Approaches

Accurate diagnosis of canine leptospirosis requires integration of clinical suspicion, routine clinicopathologic data, and specific laboratory testing. The principal diagnostic modalities are the microscopic agglutination test (MAT), polymerase chain reaction (PCR), and bacterial culture. Each method has distinct strengths and limitations.

Microscopic Agglutination Test (MAT)

The MAT remains the serological reference standard for leptospirosis diagnosis. The assay detects agglutinating antibodies (primarily IgM and IgG) against a panel of live leptospiral serovars representative of those circulating in the region [24]. Serial two-fold dilutions of patient serum are incubated with live leptospires; the endpoint titer is the highest dilution at which 50% agglutination is observed under dark-field microscopy.

Interpretation: A single titer of 1:800 or higher in a dog with compatible clinical signs is considered presumptive evidence of recent infection [25]. Paired acute and convalescent sera (collected 2 to 4 weeks apart) demonstrating a four-fold or greater rise in titer confirm active infection. However, MAT has several limitations: (1) cross-reactivity among serogroups complicates serovar-specific diagnosis; (2) antibodies may be absent early in infection (first 5 to 7 days); (3) prior vaccination can produce low to moderate titers (typically 1:100 to 1:400) that confound interpretation [26, 27]. The MAT does not distinguish between infection and vaccination unless a four-fold rise is documented.

Polymerase Chain Reaction (PCR)

PCR-based methods detect leptospiral DNA in blood, urine, or tissue samples. Real-time PCR assays targeting conserved genes such as lipL32, secY, or 16S rRNA offer high sensitivity and specificity, with detection limits as low as 10 to 100 leptospires per reaction [28, 29]. PCR is particularly valuable during the acute leptospiremic phase when serology may be negative. Urine PCR can detect shedding during convalescence and in chronic carriers [30].

Advantages: Rapid turnaround (hours), no requirement for viable organisms, and ability to differentiate pathogenic from saprophytic Leptospira through specific gene targets. Multiplex PCR panels can simultaneously detect other canine pathogens, aiding in differential diagnosis [31].

Limitations: PCR cannot distinguish between live and dead organisms, and false negatives may occur due to intermittent shedding, low bacterial load, or PCR inhibitors in urine (e.g., urea, hemoglobin) [32]. Blood PCR is most sensitive during the first week of illness; urine PCR sensitivity peaks after the second week [33].

Bacterial Culture

Culture isolation of Leptospira from blood, urine, or tissues provides definitive diagnosis and enables serovar identification. However, culture is technically demanding, slow (weeks to months), and has low sensitivity (approximately 10 to 50%) due to the fastidious nature of the organism [34]. Specialized media such as Ellinghausen-McCullough-Johnson-Harris (EMJH) medium are required, and contamination is common. Culture is rarely used in routine clinical practice but remains essential for epidemiological surveillance and vaccine strain selection [35].

Other Diagnostic Tests

Enzyme-linked immunosorbent assay (ELISA): Commercial ELISA kits detecting anti-Leptospira IgM and IgG antibodies are available. IgM ELISA can identify acute infection earlier than MAT in some cases, but cross-reactivity with vaccine-induced antibodies remains a concern [36]. The Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus provides a methodological parallel, though the target antigen differs.

Dark-field microscopy: Direct visualization of leptospires in urine or blood is rapid but suffers from poor sensitivity and requires significant expertise. It is not recommended as a sole diagnostic method [37].

Point-of-care tests: Lateral flow immunochromatographic assays for leptospiral antibodies have been developed but generally show lower sensitivity and specificity compared to MAT and PCR [38].

Diagnostic Algorithm

A recommended diagnostic algorithm for suspected canine leptospirosis is presented in Figure 1.

flowchart TD
    A[Clinical suspicion: fever, AKI, icterus, pulmonary hemorrhage], > B{Acute phase (<7 days)}
    B, >|Yes| C[Blood PCR + MAT acute serum]
    B, >|No| D[Urine PCR + MAT acute serum]
    C, > E{Results}
    D, > E
    E, >|PCR positive, MAT negative or low titer| F[Confirm acute leptospiremia]
    E, >|PCR negative, MAT high titer (>=1:800)| G[Presumptive recent infection]
    E, >|Both negative| H[Consider paired serology in 2-4 weeks]
    H, > I{Four-fold rise?}
    I, >|Yes| J[Confirmed infection]
    I, >|No| K[Alternative diagnosis]
    F, > L[Initiate treatment and report zoonotic risk]
    G, > L
    J, > L

Figure 1. Diagnostic algorithm for canine leptospirosis integrating PCR and MAT.

Zoonotic Risk and One Health Implications

Canine leptospirosis is a zoonotic disease of major public health concern. Dogs serve as sentinel hosts and potential sources of human infection through direct contact with urine or contaminated environments [39]. The zoonotic risk is particularly relevant for veterinary personnel, pet owners, and laboratory workers who handle infected animals or their specimens.

Transmission to humans occurs via the same routes as in dogs: penetration of mucous membranes or abraded skin by leptospires in water, soil, or urine. Human leptospirosis ranges from mild flu-like illness to severe Weil's disease (icterus, renal failure, hemorrhage) and pulmonary hemorrhage syndrome [40]. The serovars most commonly associated with human disease vary by region but include Icterohaemorrhagiae, Canicola, Pomona, and Grippotyphosa [41].

The One Health framework emphasizes the interconnectedness of human, animal, and environmental health in leptospirosis control. Dogs living in close proximity to humans, particularly in urban slums or rural farming communities, may amplify environmental contamination and increase human exposure risk [42]. Surveillance of canine seroprevalence can provide early warning of circulating serovars and guide public health interventions [43].

Vaccination of dogs reduces clinical disease and urinary shedding, thereby decreasing zoonotic transmission risk. However, currently available bacterin vaccines provide serovar-specific immunity and do not cover all pathogenic serovars [44]. The emergence of serovars not included in vaccines (e.g., Grippotyphosa, Bratislava) underscores the need for ongoing epidemiological monitoring and vaccine updates [45].

Biosecurity measures for veterinary clinics include use of personal protective equipment (gloves, goggles, impermeable gowns) when handling suspected cases, disinfection of contaminated surfaces with bleach or quaternary ammonium compounds, and proper disposal of urine-contaminated waste [46]. Owners should be counseled on the zoonotic risk and advised to avoid contact with their dog's urine during treatment and convalescence.

Prevention and Control

Prevention of canine leptospirosis relies on vaccination, environmental management, and owner education. Vaccination protocols should follow regional guidelines and include serovars prevalent in the practice area. Annual revaccination is recommended for at-risk dogs [47]. Environmental control measures include restricting access to stagnant water, rodent control, and prompt removal of standing water sources.

Antimicrobial therapy for confirmed cases typically involves doxycycline (5 mg/kg PO q12h for 14 days) to eliminate leptospiremia and renal carriage. Penicillin derivatives (e.g., ampicillin, amoxicillin) are used for initial treatment of acute disease but do not clear renal carriage; a subsequent course of doxycycline is required [48]. Supportive care for AKI, hepatic dysfunction, and coagulopathy is critical for survival.

Conclusion

Canine leptospirosis remains a diagnostically challenging and zoonotically important disease. The variable clinical presentation, shifting serovar epidemiology, and limitations of current diagnostic tests necessitate a multifaceted approach combining clinical acumen, molecular and serological testing, and an understanding of local disease ecology. The One Health perspective is essential for effective surveillance and control, as canine infections reflect environmental contamination and pose direct risks to human health. Continued research into improved diagnostics, broader-spectrum vaccines, and rapid point-of-care tests will enhance our ability to manage this re-emerging zoonosis.

References

[1] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[2] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[3] Goldstein RE. Canine leptospirosis. Vet Clin North Am Small Anim Pract. 2010;40(6):1091-1101.

[4] Sykes JE, Hartmann K, Lunn KF, et al. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1-13.

[5] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs: 1996-2002. J Am Vet Med Assoc. 2004;225(1):72-77.

[6] Moore GE, Guptill LF, Glickman NW, et al. Canine leptospirosis, United States, 2002-2004. Emerg Infect Dis. 2006;12(3):501-503.

[7] Ellis WA. Animal leptospirosis. Curr Top Microbiol Immunol. 2015;387:99-137.

[8] Mayer-Scholl A, Luge E, Draeger A, et al. Distribution of Leptospira serogroups in dogs from Berlin, Germany. Vector Borne Zoonotic Dis. 2013;13(11):790-792.

[9] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. J Vet Intern Med. 2010;24(6):1277-1282.

[10] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[11] Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501.

[12] Prescott JF, McEwen B, Taylor J, et al. Resurgence of leptospirosis in dogs in Ontario: recent findings. Can Vet J. 2002;43(12):955-961.

[13] Matsunaga J, Barocchi MA, Croda J, et al. Pathogenic Leptospira species express surface-exposed proteins belonging to the bacterial immunoglobulin superfamily. Mol Microbiol. 2003;49(4):929-945.

[14] Haake DA, Matsunaga J. Leptospiral immunoglobulin-like domain proteins: roles in virulence and immunity. Front Immunol. 2021;12:634370.

[15] Faine S, Adler B, Bolin C, et al. Leptospira and Leptospirosis. 2nd ed. Melbourne: MediSci; 1999.

[16] Nally JE, Chantranuwat C, Wu XY, et al. Alveolar septal deposition of immunoglobulin and complement parallels pulmonary hemorrhage in a guinea pig model of severe pulmonary leptospirosis. Am J Pathol. 2004;164(3):1115-1127.

[17] Arean VM. The pathologic anatomy and pathogenesis of fatal human leptospirosis (Weil's disease). Am J Pathol. 1962;40(4):393-423.

[18] Croda J, Neto AN, Brasil RA, et al. Leptospirosis pulmonary haemorrhage syndrome is associated with linear deposition of immunoglobulin and complement on the alveolar surface. Clin Infect Dis. 2010;50(6):e52-e58.

[19] Greenlee JJ, Bolin CA, Alt DP, et al. Clinical and pathologic comparison of acute leptospirosis in dogs caused by two strains of Leptospira kirschneri serovar Grippotyphosa. Am J Vet Res. 2005;66(6):1100-1107.

[20] Rentko VT, Clark N, Ross LA, et al. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235-244.

[21] Klopfleisch R, Kohn B, Gruber AD. Mechanisms of pulmonary hemorrhage in canine leptospirosis. Vet Pathol. 2010;47(4):632-637.

[22] Birnbaum N, Barr SC, Center SA, et al. Naturally acquired leptospirosis in 36 dogs: serological and clinicopathological features. J Small Anim Pract. 1998;39(5):231-236.

[23] Harkin KR, Roshto YM, Sullivan JT, et al. Clinical application of a polymerase chain reaction assay for detection of Leptospira spp. in dogs. J Am Vet Med Assoc. 2003;222(9):1224-1229.

[24] World Organisation for Animal Health (WOAH). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Chapter 3.1.12: Leptospirosis. Paris: WOAH; 2021.

[25] Miller MD, Annis KM, Lappin MR, et al. Variability in results of the microscopic agglutination test for leptospirosis in dogs. J Vet Intern Med. 2011;25(3):555-560.

[26] Barr SC, McDonough PL, Scipioni-Ball RL, et al. Serologic responses of dogs given a commercial vaccine against Leptospira interrogans serovar pomona and Leptospira kirschneri serovar grippotyphosa. Am J Vet Res. 2005;66(10):1780-1784.

[27] Midence JN, Leutenegger CM, Chandler AM, et al. Effects of recent Leptospira vaccination on whole blood real-time PCR testing in healthy client-owned dogs. J Vet Intern Med. 2012;26(1):149-152.

[28] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[29] Ahmed A, Engelberts MF, Boer KR, et al. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical materials. PLoS One. 2009;4(9):e7093.

[30] Bal AE, Gravekamp C, Hartskeerl RA, et al. Detection of leptospires in urine by PCR for early diagnosis of leptospirosis. J Clin Microbiol. 1994;32(8):1894-1898.

[31] Leutenegger CM, Klein D, Hofmann-Lehmann R, et al. Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. J Virol Methods. 1999;78(1-2):105-116.

[32] Smythe LD, Smith IL, Smith GA, et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp. BMC Infect Dis. 2002;2:13.

[33] Truccolo J, Serais O, Merien F, et al. Following the course of human leptospirosis: evidence of a critical threshold for the vital prognosis using a quantitative PCR assay. FEMS Microbiol Lett. 2001;204(2):317-321.

[34] Faine S. Guidelines for the Control of Leptospirosis. Geneva: World Health Organization; 1982.

[35] Ellis WA. The diagnosis of leptospirosis in farm animals. In: The Present State of Leptospirosis Diagnosis and Control. Dordrecht: Martinus Nijhoff; 1986:13-31.

[36] Cumberland P, Everard CO, Levett PN. Assessment of the efficacy of an IgM-ELISA and microscopic agglutination test (MAT) in the diagnosis of acute leptospirosis. Am J Trop Med Hyg. 1999;61(5):731-734.

[37] Vijayachari P, Sugunan AP, Sehgal SC. Evaluation of dark field microscopy as a rapid diagnostic test in leptospirosis. Indian J Med Res. 2001;114:54-58.

[38] Smits HL, van der Hoorn MA, Goris MG, et al. Simple latex agglutination assay for rapid serodiagnosis of human leptospirosis. J Clin Microbiol. 2000;38(3):1272-1275.

[39] Guerra MA. Leptospirosis: public health perspectives. Biologicals. 2013;41(5):295-297.

[40] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[41] Pappas G, Papadimitriou P, Siozopoulou V, et al. The globalization of leptospirosis: worldwide incidence trends. Int J Infect Dis. 2008;12(4):351-357.

[42] Reis RB, Ribeiro GS, Felzemburgh RD, et al. Impact of environment and social gradient on Leptospira infection in urban slums. PLoS Negl Trop Dis. 2008;2(4):e228.

[43] Dupouey J, Faucher B, Edouard S, et al. Human leptospirosis: an emerging risk in Europe? Comp Immunol Microbiol Infect Dis. 2014;37(2):77-83.

[44] Klaasen HL, Molkenboer MJ, Vrijenhoek MP, et al. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Rec. 2003;152(25):771-775.

[45] Andre-Fontaine G, Branger C, Gray AW, et al. Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis. Vet Rec. 2003;153(6):165-169.

[46] Greene CE, Sykes JE. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier; 2012:431-447.

[47] Day MJ, Horzinek MC, Schultz RD, et al. WSAVA guidelines for the vaccination of dogs and cats. J Small Anim Pract. 2016;57(1):E1-E45.

[48] Trott DJ, Abraham S, Adler B. Antimicrobial resistance in Leptospira, Brucella, and other rarely investigated veterinary and zoonotic pathogens. Microbiol Spectr. 2018;6(4):ARBA-0013-2017.

[49] Lilenbaum W, Martins G. Leptospirosis in cattle: a challenging scenario for the understanding of the epidemiology. Transbound Emerg Dis. 2014;61(Suppl 1):63-68.

[50] Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003898.